$7.1 Million in revenue for the first nine months of fiscal 2026 from commercial sales of LYMPHIR ®
CRANFORD, N.J. , Aug. 12, 2026 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), an oncology-focused biopharmaceutical company and majority-owned subsidiary of Citius Pharmaceuticals,...
New institutional accounts ordering LYMPHIR increased 78% quarter over quarter
Expanded commercial and medical affairs teams expected to be fully operational throughout the U.S. by August
Investigator-initiated study data presented May 30, 2026, at the American Society of Clinical Oncology (ASCO) Annual Meeting demonstrated durable responses and manageable tolerability in heavily pre-treated...
24% Objective Response Rate, with an average of 21.1 month Duration of Response in responders, and favorable safety profile signals potential of LYMPHIR to augment immune checkpoint inhibitor efficacy
$5.6 Million in net revenue for the first half of fiscal 2026 from ongoing launch of LYMPHIR ®
$5.6 million in net revenue for the first half of fiscal 2026 as LYMPHIR ® launch progresses Up to $36.5 million in debt and equity capital secured Broad...
Order fulfilment expands international patient access to LYMPHIR following initial U.S. launch
CRANFORD, N.J. , April 24, 2026 /PRNewswire/ -- Citius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius Pharma" or the "Company"), a biopharmaceutical company dedicated to the development and commercialization...